Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

146
Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
146

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Near-Infrared Light Triggered Upconversion Optogenetic Nanosystem for Cancer Therapy.

ACS nano·2017
Same author

Non-contact method to freely control the radiation patterns of antenna with multi-folded transformation optics.

Scientific reports·2017
Same author

Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.

Clinical drug investigation·2017
Same author

Improving Performance of Breast Cancer Risk Prediction by Incorporating Optical Density Image Feature Analysis: An Assessment.

Academic radiology·2017
Same author

Preliminary study on ultrasound-guided prostate biopsy specimen scores.

Experimental and therapeutic medicine·2017
Same author

Characterization of Continuous and Pulsed Emission modes of a Hybrid Micro Focus X-ray Source for Medical Imaging Applications.

Nuclear instruments & methods in physics research. Section A, Accelerators, spectrometers, detectors and associated equipment·2017

相关实验视频

Updated: Jun 16, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.5K

针对受体的乳球菌乳糖减轻了Clostridioides difficile感染的发生.

Yue Zhang1, Wei Sun2, Hao Wu3

  • 1Department of Pharmaceutical Engineering, School of Chemical Engineering and Technology, Tianjin University, Tianjin 300072, PR China.

Microbiological research
|June 13, 2025
PubMed
概括

改造的乳球球菌通过产生尼来有效地向Clostridioides difficile感染. 脂质涂层细菌显示出针对复发性CDI的增强治疗潜力,优于目前的治疗方法.

关键词:
凝聚力 凝聚力 凝聚力克洛斯特里迪奥伊德困难感染.乳球球菌 (lactococcus lactis) 是一种乳球菌.尼辛尼斯尼辛尼斯尼辛尼斯尼辛尼斯在RCDI中,RCDI是指RCDI.对ROS有反应的脂质膜.

更多相关视频

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.0K
Author Spotlight: Methods for Electroporation and Transformation Confirmation in Limosilactobacillus reuteri DSM20016
11:04

Author Spotlight: Methods for Electroporation and Transformation Confirmation in Limosilactobacillus reuteri DSM20016

Published on: June 23, 2023

3.4K

相关实验视频

Last Updated: Jun 16, 2025

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291
06:51

Cefoperazone-treated Mouse Model of Clinically-relevant Clostridium difficile Strain R20291

Published on: December 10, 2016

12.5K
A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment
12:58

A Protocol to Characterize the Morphological Changes of Clostridium difficile in Response to Antibiotic Treatment

Published on: May 25, 2017

9.0K
Author Spotlight: Methods for Electroporation and Transformation Confirmation in Limosilactobacillus reuteri DSM20016
11:04

Author Spotlight: Methods for Electroporation and Transformation Confirmation in Limosilactobacillus reuteri DSM20016

Published on: June 23, 2023

3.4K

科学领域:

  • 微生物学 微生物学
  • 生物技术是生物技术.
  • 胃肠病学 胃肠病学

背景情况:

  • 工程细菌对于结直肠疾病管理至关重要.
  • 乳球菌生产尼以抑制Clostridioides difficile. 这种疾病.
  • 局限性包括尼的生产不足,缺乏有针对性的释放,和弱殖民.

研究的目的:

  • 改造L. lactis以提高粘附性和治疗效果.
  • 开发一个针对尼辛生产的有针对性的交付系统.
  • 为了评估对Clostridioides difficile感染 (CDI) 和复发性CDI (rCDI) 的疗效.

主要方法:

  • 改造的L. lactis (Lla+) 表达C. difficile粘附蛋白Cwp8以增加粘附性.
  • 使用ROS响应性脂质膜进行封装,创建了涂上脂质膜的L. lactis (LCL).
  • 在肠道炎症的细胞模型和小鼠模型中评估了体外和体内疗效.

主要成果:

  • 与野生型L. lactis.相比,Lla+的粘附度增加了1.3倍.
  • 在对炎症刺激和C. difficile的反应中,LCL显示了向的尼释放.
  • 在复发性CDI模型中,LCL显著降低了60%的C. difficile存活率,并且表现优于fidaxomicin.

结论:

  • 封装方法作为一个可行的交付平台,以准炎症肠道.
  • 改造的L. lactis为CDI和rCDI提供了一个有希望的治疗策略.
  • 益生菌可以扩展为胃肠道疾病的有效药物.